Risk stratification of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization using an alpha-fetoprotein model

Egyptian Liver Journal

Table 9 Classifying BCLC A cases into low- and high-risk groups for TACE according to the AFP model

		BCLC A		Test value	P value	Sig.
		Low-risk	High-risk
		No. = 38	No. = 26
Response	Complete response	35 (92.1%)	20 (76.9%)	2.944*	0.086	NS
	Partial response	3 (7.9%)	6 (23.1%)
	Stationary disease	0 (0.0%)	0 (0.0%)
	Progressive disease	0 (0.0%)	0 (0.0%)
Recurrence	No recurrence	9 (25.7%)	7 (35.0%)	0.532*	0.466	NS
Recurrence	Recurrence	26 (74.3%)	13 (65.0%)	0.532*	0.466	NS
Recurrence-free survival	Median (IQR)	12.5 (6–17)	8.5 (3–16)	− 1.177≠	0.239	NS
Recurrence-free survival	Range	3–36	3–27	− 1.177≠	0.239	NS
OS (months)	Median (IQR)	18 (15–22)	16 (12–22)	− 1.452≠	0.146	NS
OS (months)	Range	10–42	8–32	− 1.452≠	0.146	NS